Medical Xpress September 17, 2023
Carla K. Johnson

The psychedelic drug MDMA can reduce symptoms of post-traumatic stress disorder, researchers reported in a new study published Thursday.

The company sponsoring the said it plans later this year to seek U.S. approval to market the , also known as ecstasy, as a PTSD treatment when combined with talk therapy.

“It’s the first innovation in PTSD treatment in more than two decades. And it’s significant because I think it will also open up other innovation,” said Amy Emerson, CEO of MAPS Public Benefit Corporation, the research sponsor.

Earlier this year, Australia became the first country to allow psychiatrists to prescribe MDMA and psilocybin, the psychoactive ingredient in psychedelic mushrooms. The drugs are gaining wider cultural acceptance in the U.S....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Provider, Survey / Study, Trends
Mental health organization taps Ascension executive as CEO
Where mental health ranks among Americans' healthcare priorities: 3 findings
Employers Reap $190 for Every $100 Invested in Behavioral Health
The growing movement to destigmatize mental health in nursing licensure
Little Otter Raises $9.5M for Family Mental Health

Share This Article